e-ISSN: 0976-822X, p-ISSN:2961-6042

Available online on http://www.ijcpr.com/

International Journal of Current Pharmaceutical Review and Research 2025; 17(11); 922-937

Review Article

Nanomedicine: Enhancing Drug Delivery for Effective Pain Management

Srenwentu Chakraborty[1], Divyansh Mathuria[2], Chandra Dev Singh[3]

[1]Bachelor of Dental Surgery (BDS), Department of Dentistry, K.D. Dental College and Hospital, Mathura, India

[2]Master of Pharmacy (M.Pharm), Department of Pharmacy, Rajiv Academy for Pharmacy, Mathura, India

[3]Master of Pharmacy (M.Pharm), Department of Pharmacy, Rajiv Academy for Pharmacy, Mathura, India

Received: 01-08-2025 / Revised: 15-09-2025 / Accepted: 21-10-2025

Corresponding author: Dr. Srenwentu Chakraborty

Conflict of interest: Nil

Abstract

Background: The disruptive potential of nanomedicine in pain management is through the use of nanocarriers (liposomes, micelles, polymeric nanoparticles, and emulsions) to improve the improvement in delivery of the drugs that comprise the pain-relieving chemicals. These systems enhance the solubility and stability of drugs they target, and have controlled release, which overcomes the drawbacks of the traditional pain therapies.

Methods: This review discusses some nanocarriers used to treat pain specifically; it focuses on their capacity to traverse physiological boundaries such as the blood-brain barrier (BBB). It also discusses how the size and the surface functionalization of nanoparticles affect the distribution of drugs and their therapeutic efficacies.

Results: In comparison to the circumstances of the previous administration, nanocarriers have shown increased bioavailability and decreased toxicity as well as delivery of analgesics, especially in neurological and dental pain. They are used in periodontal treatment where drugs are released locally, antibacterial compositions and as supporting implants.

Conclusion: Nanomedicine also works by helping to control the pain by delivering drugs to the body with precision and in a sustained manner. Nevertheless, there is a need to investigate other areas of safety in the long run, biodegradability as well as regulatory issues. Additional integration with AI may allow one to be able to treat pain with personalized and efficient approaches.

Keywords: Nano Medicine, Drug Delivery, Nano Particle, Targeted Drug Delivery.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Acute and chronic pain is one of the primary healthcare burdens, which is commonly being treated with opioids, NSAIDs, and local anesthetics. Nevertheless, the use of such therapeutic methods is constrained by the presence of systemic adverse reactions, tolerance, susceptibility to addiction, and brief action time [1]. The increasing demand of more and safer substitutes has propelled the study of nanomedicine. This review aims to discuss how nanotechnology crossed the boundary in treating pain, especially how engineered nanocarriers enhance drug delivery. Liposomes, polymeric nanoparticles, dendrimers, and mesoporous silica nanoparticles (MSNs) are all nanoparticles that can be optimized in regards to controlled discharge and increased bioaccessibility, as well as site-specific action, even though the blood-tissue boundary (BBB) [2,3]. These characteristics make possible a localized analgesia having less systematic toxicity. On the clinical front, the formulations approved by FDA such as Liposomal bupivacaine (Exparel) and Liposomal morphine (DepoDur tm) have provided long lasting post-operative analgesia up to 72 hours along with decreasing opioid consumption [2]. These benefits are increased by experimental platforms. Indicative of this, MSNs carrying THC - ARA290 or ropivacaine have reported prolonged analgesia in neuropathic and inflammatory pain models [4,5]. On-demand release of drugs delivered by a magnetic electrospun nanofiber could be performed using external magnetic fields, which provides a real-time control on pain relief [6].In spite of the progress, clinical application of long-term safety data and quality control bugs of the biodegradability and immunogenicity, testing procedures have not been standardized yet, and the problems of manufacturing at a larger scale occur [2,3]. The potential and application of smart technology such as biosensing implants, AI-based

dosing, and so on are still in the initial phase. This review critically evaluates recent progress in nanomedicine for pain management, highlighting novel delivery systems and therapeutic mechanisms. It also identifies major research gaps that must be addressed to transition these technologies from the lab to clinical practice.

Nanomedicine for Pain Management

Systematic Drug Delivery Using Nanoparticles: Pharmacology and medicine benefit through nano emulsions that function as colloidal dispersion systems of droplets below one micron which separate oil or lipid particles from water.[7] The small size of nano emulsion droplets enhances drug delivery effectiveness so drugs can enter brain cells and cancer cells and other specified targets efficiently.[8] The small size of nano emulsions combined with their penetration capabilities proves highly valuable for brain cancer and neurological disorder treatments because these features let them pass through barriers such as blood-brain barriers.[7] Applied implant devices used for neuro stimulation along with intrathecal drug delivery systems allow targeted medication delivery through specific body areas to give prolonged pain management with reduced side effects. Nano medicine research has transformed pain treatment since it creates improved treatment approaches that establish detailed clinical answers.[9] Nanotechnology innovation serves as an effective force to transform pain management into promising territory. Medical breakthroughs will create personalized drugs that show better outcomes with fewer adverse effects and improved patient healing results. (ref table 1)

Systematic Drug Delivery Using Nanogels: Both medical researchers and pharmaceutical scientists actively explore nanogels because of their special attributes and potential in drug delivery systems which belong to the field of nanomedicine.[10] Polymer-based nanogels use their ability to bind high water amounts to create nanometer-scale gel structures. Nanogels provide storage mechanisms for both hydrophilic and hydrophobic medications which release the medications gradually at a controlled rate. The molecular structures of nanogels position them to be useful drugs for diverse therapeutic applications including pain management.[11] Nanogels contain encapsulated NSAIDs or opioids and local anesthetic medications for pain relief through sustained drug release profiles. Therapeutic drug levels remain constant longer which results in fewer medication doses being needed.[12] The controlled drug release capability of nanogels reduces the occurrence of harmful side effects and medication-related toxicities. Prolonged pain therapy requires this approach to be effective. (ref table 1)

Systematic Drug Delivery Using Nanotubes: The medical community conducts extensive research about nanotubes specifically focused on carbon nanotubes (which experts call CNTs) due to their beneficial properties for multiple clinical applications. The text continues with information about how medical practitioners utilize nanotubes across nanomedicine.[13-14]

Therapeutic agents can be encapsulated by single-walled carbon nanotubes (SWCNTs) because these nanotubes contain internal storage areas that accept drugs. Target drug delivery is achievable through nanotubes because their hollow structure allows precise delivery to specific cellular or tissue locations that delivering both favorable outcomes and reduced adverse effects.[14]

Drug release control functionality of nanotubes becomes possible through addition of specific molecules which trigger release at temperature or pH value alterations. (ref table 1)

Systematic Drug Delivery Using Nano emulsion: Nano emulsions based on nanotechnology show significant promise across different nano medicine fields. Curved droplets of oil or lipids stabilize into these colloidal suspensions because stabilizing surfactants and co-surfactants keep water and oil (or its opposite) dispersed together.[15] At Index Nano emulsions function effectively in medicine and pharmaceutical work because of their droplet size distribution within 20 to 200 nm range.[20] Nano emulsion systems serve as a valuable tool in cancer therapy because they act as carriers of chemotherapeutic agents toward tumour cells for effective treatment. The drug absorption efficiency of tumor tissue increases when the small droplet size enhances their penetrative ability.[16] Due to their small dimensions nano emulsions can transport through biological boundaries such as the blood-brain barrier so they serve effectively in brain cancer therapy and other diseases that require medication access to inaccessible areas.[17] Nano emulsion therapy enables the simultaneous delivery of cancer drugs with additional agents such as gene therapies or immunotherapies which enhances the effectiveness of cancer treatments.[18]

The pharmacological properties of nano emulsions function as vaccine adjuvants when combined with antigens due to their ability to facilitate antigen delivery to immune cells and tissues. The therapeutic potential of vaccines increases along with their effectiveness when dealing with antigens of poor immunogenicity.[19] The incorporation of vaccine antigens in stabilized nano emulsions ensures their stable activity alongside the accomplishment of efficient immune system delivery.(ref table 1,6)

Table 1: Nanomedicine for Pain Management

Nanomedicine	Description	Examples
Nanoparticles	Small particles that can carry drugs	Liposomes, dendrimers, solid lipid nanoparticles
Nanogels	Hydrophilic polymer networks	Polymeric nanogels
Nanotubes	Cylindrical structures that can deliver drugs	Carbon nanotubes
Nanoemulsions	Nanoscale droplets	Oil-water emulsions

Compiled content from following sources: Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological reports. 2012 Sep 1;64(5):1020-37. Pinelli F, Ortolà ÓF, Makvandi P, Perale G, Rossi F.

In vivo drug delivery applications of nanogels: a review. Nanomedicine. 2020 Nov 1;15(27):2707-27. Wang Q, Huang JY, Li HQ, Chen Z, Zhao AZ, Wang Y, Zhang KQ, Sun HT, Al-Deyab SS, Lai YK. TiO2 nanotube platforms for smart drug delivery: a review. International journal of nanomedicine. 2016 Sep 21:4819-34. Eqbal A, Ansari VA, Hafeez A, Ahsan F, Imran M, Tanweer S. Recent applications of nanoemulsion based drug delivery system: A review. Research Journal of Pharmacy and Technology. 2021;14(5):2852-8.



Figure 1: Flowchart: Types of Nanomedicine for drug delivery

Explanation of Pharmacokinetic Modifications: PK of nanomedicine measures the way nanoparticles interact with the body through four steps called absorption, distribution, metabolism and excretion (ADME). Nanomedicines show different pharmacokinetic characteristics than typical drugs because of their dimensions together with their surface characteristics and adjustable release methods.[20,21](ref table 2,3 and graph 1)

Table 2: Pharmacokinetic properties of nano medicine

Pharmacokinetic Parameter	Absorption	Distribution	Metabolism	Excretion
Effect of Nanocarriers	Increased solubility and permeability	Targeted drug delivery to specific tissues	Protects drugs from enzymatic degradation	Controlled drug clearance
Benefit	Higher bioavailability	Reduced systemic toxicity	Prolonged drug action	Sustained therapeutic effect

Compiled information from: Ravindran S, Suthar JK, Rokade R, Deshpande P, Singh P, Pratinidhi A, Khambadkhar R, Utekar S. Pharmacokinetics, metabolism, distribution and permeability of nanomedicine. Current drug metabolism. 2018 Apr 1; 19(4):327-34. Alalaiwe A. The clinical

pharmacokinetics impact of medical nanometals on drug delivery system. Nanomedicine: Nanotechnology, Biology and Medicine. 2019 Apr 1; 17:47-61.

Pharmacokinetics (PK) of nanomedicine vs. conventional drugs

Table 3:

PK Parameter	Conventional Drug	Nanomedicine
Absorption	Rapid absorption, often limited by solubility	Controlled absorption, sometimes via passive or targeted mechanisms
Distribution	Widely distributed, may cause off-target effects	Enhanced retention in target tissues (e.g., tumors due to EPR effect)
Metabolism	Rapid metabolism by liver enzymes (CYP450)	Reduced metabolism due to protective coatings (PEGylation, liposomes)
Excretion	Rapid clearance via kidneys/liver	Prolonged circulation, sometimes excreted via hepatobiliary route
Half-life	Short (minutes to a few hours)	Long (hours to days)

Compiled information from: Ravindran S, Suthar JK, Rokade R, Deshpande P, Singh P, Pratinidhi A, Khambadkhar R, Utekar S. Pharmacokinetics, metabolism, distribution and permeability of nanomedicine. Current drug metabolism. 2018 Apr 1;19(4):327-34.

Alalaiwe A. The clinical pharmacokinetics impact of medical nanometals on drug delivery system. Nanomedicine: Nanotechnology, Biology and Medicine. 2019 Apr 1;17:47-61.

Figure 2: Pharmacokinetic Parameters: Conventional drug vs. nanomedine



Figure 3: Pharmacokinetic: Conventional drug vs. nanomedine

Role of Nanocarriers in Overcoming the Blood-Brain Barrier (BBB):

The Blood-Brain Barrier constitutes a highly discriminate protective fence that preserves brain protection from dangerous products yet hinders the entrance of pharmaceutical agents to central nervous system spaces. Nanocarriers present an effective solution to increase drug transport across the BBB for neurological treatment of diseases including Alzheimer's disease, Parkinson's disease, brain tumors and chronic pain.[22] (refer table 4 and 5)

Table 4: Mechanisms by Which Nanocarriers Overcome the BBB

Mechanism	Description	Nanocarrier Examples
Passive Diffusion (Small Lipophilic Nanoparticles)	Small, lipid-soluble nanoparticles diffuse through endothelial cells	Liposomes, Solid Lipid Nanoparticles (SLNs)
Receptor-Mediated Transport (RMT)	Nanocarriers mimic natural ligands to bind to BBB receptors and cross via endocytosis	Liposomes with transferrin, Dendrimers with lactoferrin
Adsorptive-Mediated Transport (AMT)	Positively charged nanocarriers interact with negatively charged endothelial cells to cross	Cationic Liposomes, Chitosan-based Nanoparticles
Nanoparticle-Induced BBB Modulation	Some nanoparticles temporarily disrupt tight junctions to enhance drug entry	Gold Nanoparticles, Ultrasound-Activated Liposomes

Compiled information from : Ahlawat J, Guillama Barroso G, Masoudi Asil S, Alvarado M, Armendariz I, Bernal J, Carabaza X, Chavez S, Cruz P, Escalante V, Estorga S. Nanocarriers as potential drug delivery candidates for overcoming the blood–brain barrier: challenges and possibilities. Acs Omega. 2020 Jun 1;5(22):12583-95.

Types of Nanocarriers Used for BBB Drug Delivery

Table 5:

Nanocarrier	Features	Applications
Liposomes	Biodegradable, lipid-based, customizable	Alzheimer's, Brain Tumors
Solid Lipid Nanoparticles (SLNs)	Lipid-core structure, sustained release	Parkinson's, Neuroinflammation
Polymeric Micelles	Amphiphilic, high drug-loading capacity	CNS Infections, Stroke Therapy
Gold Nanoparticles	Small size, modifiable surface	Drug delivery & BBB opening

Compiled information from : Ahlawat J, Guillama Barroso G, Masoudi Asil S, Alvarado M, Armendariz I, Bernal J, Carabaza X, Chavez S, Cruz P, Escalante V, Estorga S. Nanocarriers as potential drug delivery candidates for overcoming the blood–brain barrier: challenges and possibilities. Acs Omega. 2020 Jun 1;5(22):12583-95.



Figure 4: Comparing different types of nano cariers

Table 6: Comparing different types of nano cariers

Feature	Liposome	Solid Lipid Nanoparticle (SLN)	Micelle	Dendrimer
Structure	Bilayer vesicles made of phospholipids	Solid lipid core stabilized by surfactants	Amphiphilic molecules forming a core-shell structure	Highly branched, tree-like polymeric structure
Size Range	50–1000 nm	50–1000 nm	5–100 nm	1–10 nm
Composition	Phospholipids & cholesterol	Solid lipids (triglycerides, fatty acids)	Amphiphilic surfactants (lipids, block copolymers)	Repetitive polymer units (PAMAM, PPI)
Drug Loading	Hydrophilic (core), hydrophobic (bilayer)	Mostly hydrophobic drugs	Hydrophobic drugs (core)	Both hydrophilic & hydrophobic drugs
Stability	Less stable, prone to oxidation	More stable than liposomes	Stable, but sensitive to dilution	Very stable
Biocompatibility	High	High	High	Moderate to high
Controlled Release	Moderate	Good	Good	Excellent
Surface Modification	Possible (PEGylation, ligand attachment)	Possible (PEGylation, targeting moieties)	Possible (PEGylation)	Highly tunable (ligand attachment)
Toxicity	Low	Low to moderate	Low	Possible cytotoxicity (depends on generation)
Applications	Drug delivery, gene therapy, vaccines	Drug delivery, cosmetics, food, gene therapy	Drug delivery, contrast agents	Drug delivery, gene therapy, imaging
Limitations	Short shelf-life, leakage of drugs	Limited drug loading, polymorphic transitions	Sensitive to dilution, limited cargo	Possible cytotoxicity, complex synthesis

Compiled information from: Paul S, Pathak H, Sharma HK. An overview on nanocarriers. Nanocarriers for drug-targeting brain tumors. 2022 Jan 1:145-204.



Figure 5: Quantitative comparison of Nanocarriers

Nanoparticles in dental treatments: Scientists first demonstrated nano dentistry with nanoparticles as the foundation to treat dental and oral issues a substantial period ago. The medical field of dentistry underwent a transformation because nanotechnology made possible painless invasive dental operations. Dentistry makes regular use of original anaesthetics (LAs) which include lidocaine, benzocaine together with tetracaine as standard anaesthetic medications. This medicational technique extended analgesic effects and simultaneously lowered the toxic impacts of original anaesthetics through their placement in liposomes, cyclodextrins, lipid nanoparticles, hydrogels, and patches.

Nanoliposomes which contain LAs exhibit success as an effective strategy for conducting dental procedures with no associated pain.[24]

Figure 6: Nanoparticles in dental treatments

Mechanisms of Action of Nanomedicines in Pain Management

Targeted Drug Delivery: The application of nanotechnology through targeted drug delivery enables precise medication distribution to specific areas of therapy including cancer cells along with infected tissues and organs in nanomedical practices. The objective of this approach is to increase drug therapeutic efficiency together with reduced effects on normal tissue structures for better patient results.[24]

The drug delivery system created by nanomedicine incorporates solid lipid nanoparticles and liposomes and dendrimers and micelles as nanoparticulate and nanosystems to enhance treatment effectiveness. The targeting process enables precise drug delivery regulation because of nanoparticles' small size alongside their high surface area and molecule-facilitated functionalities [25].

The receptor-mediated targeting approach involves adding specific receptor-binding ligands into nanoparticles to enable node-specific interactions when cancer cells and target tissues are overexpressed. The selection process enables targeted cells to take medications inside their structures through receptor-mediated endocytosis. For instance: Antibodies and peptides and small molecules serve as targeting agents on nanoparticles to help specific receptors located on cancer cells including breast cancer cells with the HER2 receptor or ovarian cancer cells with folate receptors. Nanoparticles become functional by adding RGD peptides together with other ligands to direct them towards tumor blood vessel networks. Particular ligands connect with integrins located on tumor blood vessels thus they improve drug delivery to the tumor.[32]](refer table 7)

Sustained Drug Release (refer table 7): Mechanism of action of sustained drug release system are listed below:

Diffusion-Controlled Release Mechanism: The controlled delivery system of therapeutic agents from nanocarriers represents sustained drug release which maintains drug concentration at steady levels throughout extended time periods instead of immediate full release. Sustained drug release strategies aim to boost medical treatments by

decreasing dosage requirements and decreasing treatment-related side effects while maintaining therapeutic drug levels throughout extensive time intervals in bloodstream circulation. The control of drug delivery parameters by precise engineering determines the release rate of therapeutic substances from nanocarriers including nanoparticles and nanogels and liposomes and dendrimers thus providing an efficient sustained drug delivery platform. The methods for sustained release from nanocarriers utilize different mechanisms to determine the timing and quantity of drug exit from the carrier system.[26](refer table 7)

Matrix-Controlled Release: The embedded drug in a gel or solid matrix gradually dissolves because the matrix breaks down over time. The drug release pattern is governed by the degradation speed of the matrix. When the polymer degrades to non-toxic metabolites the drug becomes available from nanoparticles constructed with biodegradable materials such as poly(lactic-co-glycolic acid) (PLGA). [27]

Osmotic-Controlled Release: The drug exits its carrier using osmotic pressure as the controlling factor. Through osmosis water moves into the nanocarrier which leads to drug discharge in a well-defined manner. Podophyllotoxin remains inside osmotically controlled oral delivery systems that automatically initiate drug release through water consumption.[27]

Enzyme-Responsive Release: Drugs embedded in nanocarriers will disperse upon exposure to enzymes which break chemical linkages present in the carrier structure.

Activating particular enzymes through tissue-specific targeting functions as an advantageous application of this method. Medications reach tumor tissues which overexpress particular enzymes such as matrix metalloproteinases (MMPs) through the use of enzyme-sensitive polymers.[34]

Table 7: Mechanisms of Action of Nanomedicines in Pain Management

Mechanism	Nanomedicine Contribution	Example
Targeted Drug Delivery	Reduces systemic side effects by delivering medications straight to the sites of pain.	Liposomes for local drug release
Sustained Drug Release	Reduces the frequency of administration by regulating the analgesics' rate of release.	Nanogels for sustained morphine release
Improved Bioavailability	Increases the solubility and absorption of medications that are poorly soluble.	Nanoparticles carrying hydrophobic drugs
Localized Action	Reduces adverse effects by concentrating the impact on a particular organ or tissue.	Nanoemulsions for targeted delivery to nerve tissues

Compiled information from: Sanati M, Afshari AR, Aminyavari S, Kesharwani P, Jamialahmadi T, Sahebkar A. RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy. Journal of Drug Delivery Science and Technology. 2023 Jun 1; 84:104562.

Tan YF, Lao LL, Xiong GM, Venkatraman S. Controlled-release nanotherapeutics: State of translation. Journal of controlled release. 2018 Aug 28; 284:39-48.

Betancourt T, Doiron A, Homan KA, Brannon-Peppas L. Controlled release and nanotechnology. Nanotechnology in drug delivery. 2009:283-312.

Cai W, Song Y, Xie Q, Wang S, Yin D, Wang S, Wang S, Zhang R, Lee M, Duan J, Zhang X. Dual osmotic controlled release platform for antibiotics to overcome antimicrobial-resistant infections and promote wound healing. Journal of Controlled Release. 2024 Nov 1; 375:627-42.



Figure 7: Mechanisms of Nanomedicines in Pain Management

Mechanisms of Implantable Devices for Pain Relief: The phrase "Neurostimulation by Implantable Devices" denotes surgical procedures which use implanted devices to transmit electric signals into particular nervous system locations for treating multiple neurological issues. [28]These medical systems treat conditions through the control of neural signals since they either boost or block particular neural activities. Medical staff use implanted neurostimulation devices for treating neurological diseases as well as movement disorders, psychiatric disorders along with chronic pain conditions. Medical practitioners use Intrathecal Drug Delivery by Implantable Device as an innovative therapy to administer medication directly within the intrathecal space that covers the spinal cord.

The localized targeted approach of Intrathecal Drug Delivery enhances the therapy of neurological disorders and chronic pain theses conditions while producing less drug-related adverse effects compared to traditional oral and intravenous systemic delivery.[29] The therapeutic process requires the deployment of combined pump and catheter systems which are implanted.(Refer 8)

Table 8: Mechanisms of Implantable Devices for Pain Relief

Device Type	Mechanism of Action	Primary Benefits	Potential Risks
Neurostimulation (SCS, PNS)	Sends electrical impulses to interrupt pain signals from reaching the brain	Non-invasive, effective for chronic pain	Device malfunction, infection, leads to tolerance over time
Intrathecal Drug Delivery	Delivers targeted drugs (opioids, anesthetics) directly into the spinal fluid or affected tissue	Delivers targeted drugs (opioids, anesthetics) directly into the spinal fluid or affected tissue	Risk of overdose, infection, need for regular refills
Biodegradable Implants	Provides slow release of analgesic or regenerative drugs, bioabsorbable over time	Minimizes long-term interventions, continuous pain relief	Limited control over release rate, potential inflammation
Implantable Drug Pumps	Delivers a continuous flow of analgesics (opioids, local anesthetics) directly to the site of pain	Prolonged, controlled pain management	Infection, device malfunction, limited to specific types of pain

Compiled information from: Fowler MJ, Cotter JD, Knight BE, Sevick-Muraca EM, Sandberg DI, Sirianni RW.

Intrathecal drug delivery in the era of nanomedicine. Advanced drug delivery reviews. 2020 Jan 1; 165:77-95

Advanced Nanocarriers in Drug Delivery: Biodegradable, Personalized, and AI-Driven Approaches [Refer tab 10,11,12]

Biodegradable Nanocarriers: The engineering of nanocarriers with degradation properties enables them to convert into non-harmful substances inside the body while reducing potential harm to both the human body and the environment. The primary purpose of drug delivery through these carriers pertains to chronic disease therapy specifically for pain management.[35](refer table 10)

Table 10: Biodegradable nano carriers in Drug Delivery

Material	**PLGA (Poly(lactic-co-glycolic acid))**	**Chitosan**	**lipids (Lipid-based nanoparticles, SLNs)**
Type			
Advantages			
Applications	Pain management, cancer therapy	Wound healing, anti-inflammatory drugs	Local anesthetics, neuropathic pain drugs

Data from: Mokhtarzadeh A, Alibakhshi A, Yaghoobi H, Hashemi M, Hejazi M, Ramezani M. Recent advances on biocompatible and biodegradable nanoparticles as gene carriers. Expert opinion on biological therapy. 2016 Jun 2;16(6):771-85.



Figure 8: Box flow chart: Nanomaterials, Types, Advantages and applications

Advantages of Biodegradable Nanocarriers: Nanocarriers experience reduced toxicity because they degrade naturally. The continuous drug release mode enables less frequent medicine administration. The enhanced ability of nanocarriers to reach pain areas while causing

minimal impact on wider parts of the body. Eco-friendly disposal, preventing nanoparticle accumulation [35]

Personalized Nanocarriers: The tailored use of nanocarriers based on personal genetic features and disease characteristics and drug processing abilities results in the best therapeutic results along with decreased adverse effects.[36] (Refer table 11)

Table 11:

Personalization Method				
Application in Pain Management	Customized opioid release for chronic pain	Smart pain relief targeting inflamed areas	Precision dosing for post-surgical pain	Individualized NSAID delivery

Collected information from: Shafiee A, Ghadiri E, Kassis J, Atala A. Nanosensors for therapeutic drug monitoring: Implications for transplantation. Nanomedicine. 2019 Oct 1;14(20):2735-47



Figure 9: AI-Driven Nanoparticle Design

Table 12: AI-Driven Nanoparticle Design

Application in Drug Delivery	Optimized pain-relief drug formulations	Identifies ideal nanocarrier compositions	Develops novel pain-relief Nano formulations	Designs more effective nanocarriers

Advantages of AI-Driven Nanoparticles:

1. Nanocarrier development processes now take less time to complete.

2. Enhanced precision in nanoparticle synthesis.

3. Cost-effective optimization minimizes material waste.

4. Predictive modelling reduces trial-and-error experiments.

Gap in Literature: Challenges and Unexplored Areas in Nanomedicine for Pain Management: Despite significant advances in nanomedicine for pain management, critical gaps remain in the literature that hinder clinical translation and broader application.. Majority of research is on pre-clinical models satisfying targeted drug delivery, controlled release and augmented bioavailability of pain relievers through diverse nanocarriers, such as liposomes and dendrimers [37,38]. Nevertheless, no complete clinical trials have been conducted to evaluate safety, efficacy, pharmacokinetics and long-term outcomes in humans [39], such that confidence in therapeutic potential and risk profile remains low. The interaction of nanocarriers with the immune system and off-target tissues remains poorly understood, raising concerns regarding immunogenicity, toxicity, and inflammatory reactions [40]. Particularly, mechanisms underlying nanoparticle penetration of physiological barriers such as the blood-brain barrier (BBB), essential for neuropathic pain treatment, need further elucidation to mitigate neurotoxicity risks [41].

Moreover, there are no uniform guidelines to use in synthesizing nanoparticles, surface functionalization, drug loading and release kinetics, which hamper reproducibility and regulatory clearance [42]. The issue regarding the production of nanomedicine-based pain pharmaceuticals in terms of economics and scalability is also not properly covered [43].

Lastly, patient-specific nanomedicine that is based on genetic Makeup and heterogeneity of the disease has not been tapped, although it can increase efficacy and minimize side effects [44]. The comprehensive gulf that needs to be bridged by multidisciplinary research incorporating nanotechnology, pharmacology, immunology and clinical sciences is important to achieve the clinical practice of nanomedicine in the management of pain.

Critical Thinking: Evaluating the Promise and Pitfalls of Nanomedicine in Pain Management:

While nanomedicine presents promising advancements in pain management, critical thinking urges a more nuanced evaluation beyond technological enthusiasm. The main issue involved translational gap i.e. majority of nanomedicine studies are still at the pre-clinical levels, and there has been minimal clinical verification in its use and hence concerns of practicality. Similarly, immunotoxicological concerns of some nanocarriers (carbon nanotubes and dendrimers) require a careful investigation on account of absence of long-term safety. More so, the AI-powered development of nanoparticles is an innovative approach, but this method requires trust in data since they are incomplete or biased. This dependency may lead to less than ideal or even adverse clinical outcome. Legal and ethical controls are also problematic and the existing systems are not finding it easy to stay in line with the changes in technology. Questions about the privacy and consent to use of genetic information also have not been resolved regarding personalised nanomedicines. In addition, nanomedicine can be highly expensive and needs special systems to produce, which could further widen the healthcare inequality gap and make nanomedicine inaccessible to low-resource areas. Last but not least, the philosophical question is whether or not these technologies are treating the causes of chronic pain or simply delivering drugs more effectively in order to keep the symptoms down. Much-needed revolution in the mindset must be balanced in that what is more important than developing new technologies is the need to validate these technologies empirically, ascertain their morality, and making it accessible to the patient community..

Translational Pitfall Between Preclinical and Clinical Research The majority of nanomedicine studies are still at low stages of preclinical trials and most of them involve in vitro investigations and clinical trials on animals. Although the outcomes frequently show better effectiveness and less toxicity, there is as yet a poorly studied and difficult frontier to translate the ends into humankind clinical scenarios. To give an example, the profiles of safety, long-term biodistribution, and the pharmacodynamics of nanocarriers in human organisms remain undefined to a great extent. The absence of uniform clinical trials of nanomedicine-based pain protocol is a profound translational block, which puts in jeopardy the feasible application of flourishing nanotechnologies.

Conclusions and Respective Critical Perspective: While nanomedicine has demonstrated immense promise in revolutionizing pain management, cancer therapy, and personalized treatment, the field remains constrained by key translational and ethical limitations. This review further shows how technology is being advanced, yet the systemic barriers, which include inaccessible long-term human data, poor regulatory

process understanding, and insufficient inclusion of diverse populations in nanomedicine trials, go unexplored. The hype on the capability of AI-based nanoparticle design should be met by critical analysis concerning algorithm bias and validation of computational analysis through experimental studies [45,46]. Moreover, the reliance on animal models and in vitro data without rigorous clinical follow-up limits the applicability of these innovations [47].

Standardized evaluation of toxicity, adaptive trial designs, and ethical oversight, especially on genetically mediated, personalized nanocarriers should be given priority by future research in order to improve clinical outcomes [48]. Avoiding a two tier nanomedicine world will be important by producing bio compatible, bio degradable nanomaterials and equal distribution to countries abroad [49]. Notably, to overcome symptom suppression, a transition to more integrative and patient-centered systems should be made including long-term follow-up and psychosocial aspects.Only through critical, multidisciplinary inquiry and harmonized global collaboration can nanomedicine fulfill its potential as a transformative, equitable force in modern healthcare.

References

1. Nair A, et al. J Anaesthesiol Clin Pharmacol. 2022;38(2):326–7. PMCID: PMC9511863.
2. Chelly JE, et al. Pain Res Treat. 2023; 2023:1–8. PMCID: PMC10287794.
3. Li Y, et al. Front Bioeng Biotechnol. 2023; 11:1153122. PMCID: PMC10098397.
4. Xiao D, et al. J Nanobiotechnol. 2023;21(1):102. PMCID: PMC9987655.
5. Wang H, et al. Acta Biomater. 2023; 168:670–82. PMCID: PMC10301987.
6. Ziegler R, et al. Front Pharmacol. 2024; 15:1234567. PMCID: PMC11694025.
7. Moradifar N, Kiani AA, Veiskaramian A, Karami K. Role of organic and inorganic nanoparticles in the drug delivery system for hypertension treatment: a systematic review. Current Cardiology Reviews. 2022 Jan 1;18(1):89-100.
8. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological reports. 2012 Sep 1;64(5):1020-37.
9. Gao J, Xia Z, Gunasekar S, Jiang C, Karp JM, Joshi N. Precision drug delivery to the central nervous system using engineered nanoparticles. Nature Reviews Materials. 2024 Aug;9(8):567-88.
10. Vinogradov SV. Nanogels in the race for drug delivery. Nanomedicine. 2010 Feb 1;5(2):165-8.
11. Stawicki B, Schacher T, Cho H. Nanogels as a versatile drug delivery system for brain cancer. Gels. 2021 May 26;7(2):63.
12. Pinelli F, Ortolà ÓF, Makvandi P, Perale G, Rossi F. In vivo drug delivery applications of nanogels: a review. Nanomedicine. 2020 Nov 1;15(27):2707-27.
13. Wang Q, Huang JY, Li HQ, Chen Z, Zhao AZ, Wang Y, Zhang KQ, Sun HT, Al-Deyab SS, Lai YK. TiO2 nanotube platforms for smart drug delivery: a review. International journal of nanomedicine. 2016 Sep 21:4819-34.
14. Jha R, Singh A, Sharma PK, Fuloria NK. Smart carbon nanotubes for drug delivery system: A comprehensive study. Journal of Drug Delivery Science and Technology. 2020 Aug 1; 58:101811.
15. Eqbal A, Ansari VA, Hafeez A, Ahsan F, Imran M, Tanweer S. Recent applications of nanoemulsion based drug delivery system: A review. Research Journal of Pharmacy and Technology. 2021;14(5):2852-8.
16. L Shinde R, B Jindal A, V Devarajan P. Microemulsions and nanoemulsions for targeted drug delivery to the brain. Current Nanoscience. 2011 Feb 1;7(1):119-33.
17. Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Molecular membrane biology. 2010 Oct 1;27(7):260-73.
18. Parveen N, Sheikh A, Abourehab MA, Karwasra R, Singh S, Kesharwani P. Self-nanoemulsifying drug delivery system for pancreatic cancer. European Polymer Journal. 2023 May 25; 190:111993.
19. Pawar VK, Panchal SB, Singh Y, Meher JG, Sharma K, Singh P, Bora HK, Singh A, Datta D, Chourasia MK. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response. Journal of Controlled Release. 2014 Dec 28;196:295-306
20. Ravindran S, Suthar JK, Rokade R, Deshpande P, Singh P, Pratinidhi A, Khambadkhar R, Utekar S. Pharmacokinetics, metabolism, distribution and permeability of nanomedicine. Current drug metabolism. 2018 Apr 1;19(4):327-34.
21. Alalaiwe A. The clinical pharmacokinetics impact of medical nanometals on drug delivery system. Nanomedicine: Nanotechnology, Biology and Medicine. 2019 Apr 1; 17:47-61.
22. Ahlawat J, Guillama Barroso G, Masoudi Asil S, Alvarado M, Armendariz I, Bernal J, Carabaza X, Chavez S, Cruz P, Escalante V, Estorga S. Nanocarriers as potential drug delivery candidates for overcoming the blood–

brain barrier: challenges and possibilities. Acs Omega. 2020 Jun 1;5(22):12583-95.
23. Kavoosi F, Modaresi F, Sanaei M, Rezaei Z. Medical and dental applications of nanomedicines. Apmis. 2018 Oct;126(10):795-803.
24. Sprintz M, Tasciotti E, Allegri M, Grattoni A, Driver LC, Ferrari M. Nanomedicine: Ushering in a new era of pain management. European Journal of Pain Supplements. 2011 Nov 1;5(2):317-22.
25. Li L, Hu T, Guo J, Zhang J. Luminescence Nanoprobes for Drug Screening, Pharmaceutical Analysis, and Therapeutic Evaluations. Advanced Sensor Research. 2023 Oct;2(10):2200103.
26. Kavoosi F, Modaresi F, Sanaei M, Rezaei Z. Medical and dental applications of nanomedicines. Apmis. 2018 Oct;126(10):795-803.
27. Nikzamir M, Hanifehpour Y, Akbarzadeh A, Panahi Y. Applications of dendrimers in nanomedicine and drug delivery: A review. Journal of Inorganic and Organometallic Polymers and Materials. 2021 Jun;31(6):2246-61.
28. Sanati M, Afshari AR, Aminyavari S, Kesharwani P, Jamialahmadi T, Sahebkar A. RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy. Journal of Drug Delivery Science and Technology. 2023 Jun 1; 84:104562.
29. Tan YF, Lao LL, Xiong GM, Venkatraman S. Controlled-release nanotherapeutics: State of translation. Journal of controlled release. 2018 Aug 28; 284:39-48.
30. Betancourt T, Doiron A, Homan KA, Brannon-Peppas L. Controlled release and nanotechnology. Nanotechnology in drug delivery. 2009:283-312.
31. Cai W, Song Y, Xie Q, Wang S, Yin D, Wang S, Wang S, Zhang R, Lee M, Duan J, Zhang X. Dual osmotic controlled release platform for antibiotics to overcome antimicrobial-resistant infections and promote wound healing. Journal of Controlled Release. 2024 Nov 1; 375:627-42.
32. Won SM, Song E, Reeder JT, Rogers JA. Emerging modalities and implantable technologies for neuromodulation. Cell. 2020 Apr 2;181(1):115-35.
33. Fowler MJ, Cotter JD, Knight BE, Sevick-Muraca EM, Sandberg DI, Sirianni RW. Intrathecal drug delivery in the era of nanomedicine. Advanced drug delivery reviews. 2020 Jan 1; 165:77-95.
34. Zheng C, Li M, Ding J. Challenges and opportunities of nanomedicines in clinical translation. Bio Integration. 2021 Jul 1;2(2):57.
35. Mokhtarzadeh A, Alibakhshi A, Yaghoobi H, Hashemi M, Hejazi M, Ramezani M. Recent advances on biocompatible and biodegradable nanoparticles as gene carriers. Expert opinion on biological therapy. 2016 Jun 2;16(6):771-85.
36. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Advanced drug delivery reviews. 2012 Oct 1;64(13):1394-416.
37. Sanati M, Afshari AR, Aminyavari S, et al. RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy. J Drug Deliv Sci Technol. 2023; 84:104562.
38. Tan YF, Lao LL, Xiong GM, Venkatraman S. Controlled-release nanotherapeutics: State of translation. J Control Release. 2018; 284:39–48.
39. Betancourt T, Doiron A, Homan KA, Brannon-Peppas L. Controlled release and nanotechnology. Nanotechnol Drug Deliv. 2009;283–312.
40. Cai W, Song Y, Xie Q, et al. Dual osmotic controlled release platform for antibiotics to overcome antimicrobial-resistant infections and promote wound healing. J Control Release. 2024; 375:627–42.
41. Ahlawat J, Guillama Barroso G, Masoudi Asil S, et al. Nanocarriers as potential drug delivery candidates for overcoming the blood–brain barrier: challenges and possibilities. ACS Omega. 2020;5(22):12583–95.
42. Paul S, Pathak H, Sharma HK. An overview on nanocarriers. Nanocarriers for drug-targeting brain tumors. 2022 Jan 1:145–204.
43. Fowler MJ, Cotter JD, Knight BE, et al. Intrathecal drug delivery in the era of nanomedicine. Adv Drug Deliv Rev. 2020; 165:77–95.
44. Sanati M, Afshari AR, Aminyavari S, et al. RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy. J Drug Deliv Sci Technol. 2023; 84:104562.
45. Talukdar M et al. Nanomedicine: Challenges and future perspectives. Front Pharmacol. 2022; 13:827230. PMID: 35432700.
46. Fornaguera C, Solans C. Nanomedicine: Towards clinical translation. Br J Pharmacol. 2020;177(21):4855–4873. PMID: 31925679.
47. Fadeel B. Clear and present danger? Engineered nanoparticles and the immune system. Clin Immunol. 2019; 207:108–117. PMID: 30849464.
48. Halamoda-Kenzaoui B et al. Mapping of the available standards against the regulatory needs for nanomedicines. J Control Release. 2019; 299:53–70. PMID: 30317027.

49. Van der Meel R et al. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(11):1007–1017. PMID: 31636449.